Overview

The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, drug-drug interaction study in postmenopausal women with osteoporosis.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab
Midazolam